Voyager Therapeutics, Inc. (NASDAQ:VYGR Get Rating) major shareholder Rock Ventures Iii L.P. Third sold 100,000 shares of the stock in a transaction that occurred on Friday, January 20th. The stock was sold at an average price of $9.15, for a total value of $915,000.00. Following the transaction, ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR Get Rating) major shareholder Rock Ventures Iii L.P. Third sold 100,000 shares of the stock in a transaction that occurred on Friday, January 20th. The stock was sold at an average price of $9.15, for a total value of $915,000.00. Following the ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR Get Rating) major shareholder Ecor1 Capital, Llc sold 456,000 shares of the companys stock in a transaction on Monday, January 9th. The stock was sold at an average price of $7.67, for a total transaction of $3,497,520.00. Following the ...

- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-...

StockNews.com upgraded shares of Voyager Therapeutics (NASDAQ:VYGR Get Rating) from a hold rating to a buy rating in a research report sent to investors on Monday. Voyager Therapeutics Stock Down 5.8 % VYGR stock opened at $5.21 on Monday. The firm has a market cap of $201.14 million, a PE ratio of...